Astra Stockpiles Vaccine That Could Speed Up Biden Timeline
(Bloomberg) -- AstraZeneca Plc has begun stockpiling its Covid-19 vaccine for use in the U.S., providing a potential supply boost that could speed up President Joe Biden's inoculation timetable, should the company win regulatory authorization.
A company executive said this week it has begun production and expects to have 30 million doses ready for U.S. distribution, once it's approved by the U.S. Food and Drug Administration. AstraZeneca hasn't yet applied to the FDA and hasn't said when it will, but the U.K.-based company expects to produce 15 to 25 million doses per month for the U.S. after that.
If the FDA gives the green light, “we are expecting to start with 30 million,” Ruud Dobber, AstraZeneca's executive vice president and president of its biopharmaceuticals unit, told CNBC this week. “We're already producing at high speed as we speak, so we feel comfortable.”
The company is “on track” to eventually deliver a total of 300 million doses to the U.S., he said.
Meanwhile, Biden administration officials, speaking on condition of anonymity, said they're aware the stockpile is accumulating but declined to say how big it is.
Vaccine Availability
Biden announced this week that the U.S. would receive enough doses for nearly 300 million people, sufficient for every American adult, by the end of May, a figure that includes the three authorized U.S. vaccines: from the Pfizer Inc.-BioNTech SE partnership, Moderna Inc. and Johnson & Johnson.
Biden's White House has regularly said it doesn't make plans or sketch out timelines that rely on potential future authorization of any one vaccine, instead treating new authorizations as something of a bonus. Its public time lines rely only on shipment projections for authorized vaccines.
If the AstraZeneca stockpile languishes, it could fuel tensions over vaccine availability. Italy this week blocked a shipment of AstraZeneca's vaccines to Australia. As some countries -- chiefly the U.S., which has administered more doses than any country -- ramp up their inoculation programs, others are struggling with supply shortages.
The European Union will ask the U.S. to authorize the export of millions of doses of AstraZeneca's Covid-19 vaccine to the bloc, the Financial Times reported on Saturday. The European Commission plans to raise the matter in upcoming talks focused on increasing cooperation in the fight against Covid-19, the newspaper cited EU officials as saying.
Biden has made Covid response a cornerstone of his early administration, and has steadily announced increases in shipments.
The U.S. has ordered 300 million shots each from Moderna and Pfizer, both of which use two doses, providing enough for 300 million people. The U.S. has also ordered 100 million doses of J&J's one-dose vaccine.
Even without AstraZeneca, the U.S. has firm orders for more doses than it has people, and far more than are eligible to get shots, which aren't yet approved for people under age 16. The White House has declined to say when, or how, it would share any surplus doses with other nations, and rebuffed a request this week from Mexico's president to do so.
©2021 Bloomberg L.P.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.